We assessed the effect of stage, grade, and histologic type on cancer-specific mortality after surgery in candidates for 1 of the 4 North American ongoing immune-oncology checkpoint inhibitor trials. Important differences exist in the inclusion criteria among the 4 ongoing adjuvant trials. By generating 4 random samples, we have demonstrated that the differences in the inclusion criteria are reflected in the differences in the mortality rates.

A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality

Mazzone E.;Briganti A.;
2020-01-01

Abstract

We assessed the effect of stage, grade, and histologic type on cancer-specific mortality after surgery in candidates for 1 of the 4 North American ongoing immune-oncology checkpoint inhibitor trials. Important differences exist in the inclusion criteria among the 4 ongoing adjuvant trials. By generating 4 random samples, we have demonstrated that the differences in the inclusion criteria are reflected in the differences in the mortality rates.
2020
Adjuvant therapy
Clear cell
Immune checkpoint inhibitors
Nephrectomy
Sarcomatoid
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/108547
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
social impact